期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 27, 期 40, 页码 6844-6860出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i40.6844
关键词
Pancreatic cancer; Gemcitabine; Human nucleoside transporters; Human equilibrative nucleoside transporters; Human concentrative nucleotide transporters; Mucins
资金
- Department of Surgery at St George Hospital, UNSW
The prognosis of pancreatic cancer is poor with a very low 5-year survival rate, and research has shown that human nucleoside transporters play a crucial role in its development and chemoresistance mechanisms. This review summarizes the abnormal expression and function of these transporters in pancreatic cancer, as well as the importance of mucins associated with nucleoside transporters, current diagnostic techniques, and therapeutic treatments for pancreatic cancer.
The prognosis of pancreatic cancer is poor with the overall 5-year survival rate of less than 5% changing minimally over the past decades and future projections predicting it developing into the second leading cause of cancer related mortality within the next decade. Investigations into the mechanisms of pancreatic cancer development, progression and acquired chemoresistance have been constant for the past few decades, thus resulting in the identification of human nucleoside transporters and factors affecting cytotoxic uptake via said transporters. This review summaries the aberrant expression and role of human nucleoside transports in pancreatic cancer, more specifically human equilibrative nucleoside transporter 1/2 (hENT1, hENT2), and human concentrative nucleoside transporter 1/3 (hCNT1, hCNT3), while briefly discussing the connection and importance between these nucleoside transporters and mucins that have also been identified as being aberrantly expressed in pancreatic cancer. The review also discusses the incidence, current diagnostic techniques as well as the current therapeutic treatments for pancreatic cancer. Furthermore, we address the importance of chemoresistance in nucleoside analogue drugs, in particular, gemcitabine and we discuss prospective therapeutic treatments and strategies for overcoming acquired chemoresistance in pancreatic cancer by the enhancement of human nucleoside transporters as well as the potential targeting of mucins using a combination of mucolytic compounds with cytotoxic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据